August 18, 2017 11:22 PM ET

Healthcare Equipment and Supplies

Company Overview of Tal Medical, Inc.

Company Overview

Tal Medical, Inc., a clinical stage neuroscience company, develops non-invasive neurostimulation treatments for brain disorders. The company provides medical devices for the treatment of psychiatry and neurology disorders; and develops non-invasive sub-threshold neurostimulation platform to target brain disorders. Its Low Field Magnetic Stimulation (LFMS) technology produces a sub-threshold electric field that modulates brain circuitry involved in unipolar and bipolar depression. The company was founded in 2010 and is based in Boston, Massachusetts. Tal Medical, Inc. operates as a subsidiary of PureTech Health PLC.

501 Boylston Street

Suite 6102

Boston, MA 02116

United States

Founded in 2010

Phone:

617-456-0032

Key Executives for Tal Medical, Inc.

Chief Executive Officer, President & Director
Executive Chairman, Co-Founder & SAB Chair
Age: 74
VP, COO & Co-Founder
Director, Co-Founder & SAB Chair
Age: 66
Co-Founder & Non-Executive Director
Age: 77
Compensation as of Fiscal Year 2017.

Tal Medical, Inc. Key Developments

Tal Medical Announces Results from Two Studies of Tal Medical's LFMS Technology in Treatment-Resistant Major Depressive Disorder

Tal Medical announced results from two studies evaluating Tal's proprietary Low Field Magnetic Stimulation (LFMS) technology in treatment-resistant major depressive disorder (TR-MDD). A Tal dose optimization study did not meet statistical significance on its Hamilton Depression Rating Scale (HAMD6) primary endpoint, although it showed a rapidly-acting, trending effect across multiple measurements in a dose-dependent manner. Separately, a functional magnetic resonance imaging (fMRI) study at Weill Cornell Medical College showed a reduction in functional connectivity in brain networks associated with depression after LFMS treatment. Given these latest results and the data from the RAPID trial reported in June, company will assess the utilization of Tal resources and previously-earmarked PureTech cash and re-allocate as appropriate. Although company did not achieve statistical significance on the primary endpoint of their dosing study, the observed magnitude of the effect achieved in 2 to 4 days is on par with or higher than what antidepressant drugs typically achieve in 4 to 10 weeks and with a good safety profile. They are considering several options to potentially increase the effect size and statistical power, including working with strategic partners and trusted academic collaborators through non-dilutive sources. The data from both the dose ranging and Weill Cornell studies are encouraging and further suggest that LFMS has rapidly-acting effects on mood. Importantly, the dose-dependent effects of LFMS on self-rated as well as investigator-rated symptoms of depression seen in the dose ranging study, coupled with a highly favorable safety profile, support further work to optimize the LFMS field properties for the potential treatment of clinical depression.

Tal Medical Enrolls First Patient in Dose Optimization Study for Innovative Investigational Therapy to Treat Depression and Other Neuropsychiatric Disorders

Tal Medical announced that the first subject has been enrolled in the dose optimization study. The randomized, placebo-controlled dosing study will be conducted in 120 patients across multiple sites in the U.S. Topline data are expected in early 2017. The Company also announced that it has received positive confirmation from the U.S. Food and Drug Administration (FDA) that Tal's dosing study is a nonsignificant risk (NSR) device study. The FDA's NSR designation allows Tal to proceed with the dose optimization study in the U.S. without submitting and obtaining approval of an investigational device exemption (IDE) application because the study, as assessed by the FDA, is not considered to present a potential for serious risk to the health, safety, or welfare of a subject. NSR devices are those that are generally considered to be low risk based on their intended use in the study. Examples of NSR devices include daily wear contact lenses, dental filling materials, and jaundice monitors for infants. In 2013, Tal received initial proof-of-concept data from a randomized, double-blind, sham-controlled trial in patients with major depressive and bipolar disorders conducted by McLean Hospital, a psychiatric research hospital affiliated with Harvard Medical School. In the study, a single 20-minute treatment demonstrated rapid onset of action, substantial effect size, and a strong safety profile. Given this unique, rapid effect of LFMS treatment, the National Institute of Mental Health has selected LFMS for a multi-site clinical trial. The trial is examining the efficacy and durability of the treatment over an extended period of time in patients with major depressive disorder.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tal Medical, Inc., please visit www.talmedical.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.